The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis

(2012) Renathe Rismo et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

(2011) L. S. Kiss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation

(2011) Trine Olsen et al.   CYTOKINE

Compartmentalized Expression of Th1 and Th17 Cytokines in Pediatric Inflammatory Bowel Diseases

(2011) J. Verdier et al.   INFLAMMATORY BOWEL DISEASES

Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease

(2011) Marco Daperno et al.   Journal of Crohns & Colitis

Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease

(2011) Laurent Peyrin-Biroulet et al.   Journal of Crohns & Colitis

Candidate mucosal and surrogate biomarkers of inflammatory bowel disease in the era of new technology

(2011) Jon Florholmen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Mucosal Healing and anti TNFs in IBD

(2010) Gert Assche et al.   CURRENT DRUG TARGETS

Proinflammatory cytokines underlying the inflammation of Crohnʼs disease

(2010) Warren Strober et al.   CURRENT OPINION IN GASTROENTEROLOGY

Predictive value of epithelial gene expression profiles for response to infliximab in Crohnʼs disease‡

(2010) Ingrid Arijs et al.   INFLAMMATORY BOWEL DISEASES

Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab†

(2010) Zhe Li et al.   INFLAMMATORY BOWEL DISEASES

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis

(2009) Trine Olsen et al.   CYTOKINE

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

(2009) Filip Baert et al.   GASTROENTEROLOGY

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease

(2009) Fabian Schnitzler et al.   INFLAMMATORY BOWEL DISEASES

Infliximab therapy decreases the levels of TNF-α and IFN-γ mRNA in colonic mucosa of ulcerative colitis

(2009) Trine Olsen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Anti tumour necrosis-α therapy increases the number of FOXP3+regulatory T cells in children affected by Crohn’s disease

(2008) Ida Ricciardelli et al.   IMMUNOLOGY

IL-23/IL-17 immunity as a hallmark of Crohnʼs disease

(2008) Veera Hölttä et al.   INFLAMMATORY BOWEL DISEASES

Is the Th1/Th2 paradigm of immune regulation applicable to IBD?

(2008) Ivan J. Fuss   INFLAMMATORY BOWEL DISEASES

Signature biomarkers in Crohn's disease: toward a molecular classification

(2008) R Arsenescu et al.   Mucosal Immunology

Analyzing real-time PCR data by the comparative CT method

(2008) Thomas D Schmittgen et al.   Nature Protocols